Lead Product(s) : Cladribine
Therapeutic Area : Neurology
Study Phase : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : New real-world data show MAVENCLAD® (cladribine tablets) had lower annualised relapse rates and longer time to first relapse and time to switch than fingolimod, dimethyl fumarate and teriflunomide in relapsing multiple sclerosis patients.
Product Name : Mavenclad
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 24, 2022
Lead Product(s) : Cladribine
Therapeutic Area : Neurology
Highest Development Status : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Cladribine
Therapeutic Area : Neurology
Study Phase : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Extension to the MAGNIFY MS Trial on Mavenclad® (Magnify MS Extension)
Details : Undisclosed
Product Name : Mavenclad
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 05, 2021
Lead Product(s) : Cladribine
Therapeutic Area : Neurology
Highest Development Status : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Cladribine
Therapeutic Area : Neurology
Study Phase : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Mavenclad
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 01, 2021
Lead Product(s) : Cladribine
Therapeutic Area : Neurology
Highest Development Status : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Naproxen Sodium
Therapeutic Area : Neurology
Study Phase : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 13, 2020
Lead Product(s) : Naproxen Sodium
Therapeutic Area : Neurology
Highest Development Status : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Methoxyflurane
Therapeutic Area : Neurology
Study Phase : Phase IV
Sponsor : AXONAL | Exystat
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 10, 2019
Lead Product(s) : Methoxyflurane
Therapeutic Area : Neurology
Highest Development Status : Phase IV
Sponsor : AXONAL | Exystat
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Naloxone Hydrochloride
Therapeutic Area : Neurology
Study Phase : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Inapplicable
December 07, 2018
Lead Product(s) : Naloxone Hydrochloride
Therapeutic Area : Neurology
Highest Development Status : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Pramipexole Dihydrochloride
Therapeutic Area : Neurology
Study Phase : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 11, 2018
Lead Product(s) : Pramipexole Dihydrochloride
Therapeutic Area : Neurology
Highest Development Status : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Naproxen Sodium
Therapeutic Area : Neurology
Study Phase : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 19, 2018
Lead Product(s) : Naproxen Sodium
Therapeutic Area : Neurology
Highest Development Status : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Cladribine
Therapeutic Area : Neurology
Study Phase : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Mavenclad
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 12, 2017
Lead Product(s) : Cladribine
Therapeutic Area : Neurology
Highest Development Status : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Cladribine
Therapeutic Area : Neurology
Study Phase : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Evaluation of the Onset of Action in Highly Active MS (MAGNIFY)
Details : Undisclosed
Product Name : Mavenclad
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 06, 2017
Lead Product(s) : Cladribine
Therapeutic Area : Neurology
Highest Development Status : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable